Samjo Capital LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H203. A total of 23 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Samjo Capital LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q1 2022$563,000
-82.4%
404,963
-31.4%
0.48%
-77.6%
Q4 2021$3,198,000
-15.1%
590,000
-10.6%
2.14%
-22.6%
Q3 2021$3,769,000
+21.5%
660,000
+23.6%
2.77%
+31.8%
Q2 2021$3,103,000
+31.9%
534,000
+24.2%
2.10%
+20.3%
Q1 2021$2,352,000
+28.7%
430,000
+12.7%
1.74%
+11.9%
Q4 2020$1,828,000381,7131.56%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Virtu Financial LLC 72,452$44,0000.00%
HighMark Wealth Management LLC 6,966$4,0000.00%
UBS Group AG 26$00.00%
WELLS FARGO & COMPANY/MN 46$00.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GEODE CAPITAL MANAGEMENT, LLC 47,178$28,0000.00%
STATE STREET CORP 14,455$9,0000.00%
MILLENNIUM MANAGEMENT LLC 23,683$15,0000.00%
MORGAN STANLEY 10,611$7,0000.00%
BlackRock Inc. 74,192$45,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders